Atlas Trials

Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer

Clinical trial NCT04670978 · UNKNOWN

Trial details

NCT number
NCT04670978
Sponsor
Shandong University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Objective Response Rate
Start date
2021-03-31
Primary completion
2023-12-31
Enrollment
96

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.